ArticleNeuro-oncology advances
Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction.Neurology(R) neuroimmunology & neuroinflammation · 2025Pooled it
- Paraneoplastic Intracellular Neuropathies: A Narrative Review.Neurology and therapy · 2026Review
- Successful fresh formulation CD19 CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia. A Case Report.Frontiers in immunology · 2026Article
- A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial.Neurology open access · 2025Article
- Toward curing neurological autoimmune disorders: Biomarkers, immunological mechanisms, and therapeutic targets.Neuron · 2025Review
- Immune checkpoint inhibitor-induced anti-Hu antibody-associated gastrointestinal pseudo-obstruction: a case report and literature review.Frontiers in immunology · 2025Review
- Paraneoplastic cerebellar degeneration combined with Lambert-Eaton myasthenia gravis syndrome in a patient positive for SOX1 antibody.American journal of translational research · 2025Article
- Clinical characteristics and prognosis of paraneoplastic syndromes: a single-center cohort study in Northern China.Frontiers in immunology · 2025Article
- Review of the Longitudinal Management of Autoimmune Encephalitis, Potential Biomarkers, and Novel Therapeutics.Neurology. Clinical practice · 2024Review
- Adenylate kinase 5 (AK5) autoimmune encephalitis: Clinical presentations and outcomes in three new patients.Journal of neuroimmunology · 2022Article
- Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis.Brain communications · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParaneoplastic neurological syndromes with anti-Hu antibodies (Hu-PNS) have a very poor prognosis: more than half of the patients become bedridden and median survival is less than 12 months. Several lines of evidence suggest a pathogenic T cell-mediated immune response. Therefore, we conducted a prospective open-label phase II trial with natalizumab.
methodsTwenty Hu-PNS patients with progressive disease were treated with a maximum of three monthly natalizumab cycles (300 mg). The primary outcome measure was functional improvement, this was defined as at least one point decrease in modified Rankin Scale (mRS) score at the last treatment visit. In addition, treatment response was assessed wherein a mRS score ≤3 after treatment was defined as treatment responsive.
resultsThe median age at onset was 67.8 years (SD 8.4) with a female predominance (
conclusionsNatalizumab may ameliorate the disease course in Hu-PNS, but no superior effects above other reported immunosuppressive and immunomodulatory were observed. More effective treatment modalities are highly needed.
trial registrationhttps://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000675-13/NL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.